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Background: We prospectively studied the impact of an adherence counselor on the outcome of
patients failing antiretroviral therapy because of nonadherence. Methods: Forty-six patients,
identified as chronically nonadherent were enrolled. Individual attention was provided using the
information, motivation and behavioral methodology. HIV RNA (viral load, in copies/mL), CD4
count (in cells/[mm.sup.3]), and body weight before and after the adherence counselor were
measured. Qualitative outcome and patient satisfaction were assessed by deidentified third-party
interviews. Results: Over half completed at least 1 year; only 8 patients were lost to follow-up.
Mean CD4 counts increased significantly (P < .05) for completers at 6 and 12 months. Viral
loads decreased between baseline and 6 months. Most clients reported subjective benefit from
working with the adherence counselor. Conclusion: Although few clients showed complete
virologic suppression, the value of an adherence counselor was validated. Longer term adherence
programs should be evaluated.
Keywords: adherence; failure of medical management; compliance; counseling; HIV outcomes
Once the decision to start therapy has been determined, adherence to antiretroviral therapy is
essential for the clinical management of HIV infection. Yet multiple studies have revealed poor
adherence to antiretroviral regimens resulting in failure to suppress HIVRNA values, the
emergence of drug-resistant strains, and more rapid progression of illness to clinical and
surrogate end points. (1-8) This problem is not new. Poor adherence to medication has been
recognized as problematic since the writings of Hippocrates (460-377 BC) who advised that
physicians should "be alert to the faults of patients which often make them lie about the taking of
medicines prescribed." (9) Consequently, increased attention has been paid to the problem of
adherence and methods for promoting good adherence in recent HIV literature.
Adherence to highly active antiretroviral therapy (HAART) is a challenge for even the motivated
client. Multiple drugs, complex dosing schedules, dietary restrictions, and significant short-term
and long-term side effects are frequent complaints. Clients themselves have comorbidities that
impact adherence: mental illness, poor relationships with providers, transportation and access
issues, poverty, substance abuse, social environment and living conditions, personal belief
systems, and concomitant physical illnesses. Social prejudices against HIV/AIDS may create
further obstacles, as patients may not want colleagues, friends, or family to know about the

illness, thereby making it hard to maintain complex medication regimens. Poor relationships with
providers result in less than optimal clinical results: more than any other factor in urban HIV
clinics, missed clinic appointments correlate with unsuccessful treatment. (10)
Roberts (11) identified 5 main barriers to adherence in a series of client interviews: forgetfulness,
social and physical environment, antiretroviral regimen complexity, medication side effects, and
inadequate patient knowledge. She concluded that patients might overcome some of these
barriers by receiving better education about the nature of HIV/AIDS and the need for medication
adherence, professional and lay support, and mechanical reminders such as alarm clocks and
medisets. These results also indicate the need for additional research into how psychosocial
factors and personal beliefs impact adherence in HIV/AIDS. (12-17)
This study utilized the information, motivation, and building skills methodology (IMB) (18) and
was designed to assess whether the introduction of an adherence counselor has a positive impact
on adherence characteristics and clinical outcomes in a cohort of patients with a history of poor
adherence to medical treatment. Others have shown that success may be achieved in such
populations by assuring readiness and finding the right provider. (19) In addition to measuring
quantitative end points, we assessed qualitative information from clients about the effectiveness
of the adherence counselor to determine whether this type of program will benefit other clients,
providers, and support service agencies. Qualitative methods help to demonstrate the humanistic
perspective and are beneficial in answering psychosocial questions about how individual patients
cope with the demands of taking antiretroviral medications and living with HIV infection. At
least 95% adherence to antiretroviral therapy is necessary to limit the risk of resistance to
medications. Recognizing this, the investigators undertook this study to determine the impact of
individualized holistic attention, in the form of an adherence counseling intervention, on the
health and outlook of clients identified as recalcitrant by the study investigators.
Methods
Study Overview
The adherence counselor position was created to provide individual attention to adherence issues
for HIV-positive clients attending the immunology (HIV) clinic at the Stamford Hospital, a 300bed community teaching hospital in southwestern Connecticut. The clinic serves approximately
400 clients; at any given time about 200 are consistently and regularly using clinical services. Of
the clients using the clinic, 50% are African American and 27% are Hispanic or Latino. Greater
than 35% are drug users or former drug users, and 6% are homeless. The clinic serves a
predominantly indigent clientele. Requirements for the adherence counselor position included
excellent communication skills, compassion, spirituality, flexibility in scheduling, awareness of
the community, and an in-depth knowledge of HIV and its medical management. Funding for the
position was obtained from federal Ryan White Title II care funds provided through the State of
Connecticut Department of Public Health to Stamford CARES, a not-for-profit HIV service
organization.
From March 2000 to February 2001, 46 HIV-infected individuals older than 21 years were
consecutively identified by the infectious diseases physicians and/or the HIV nurse practitioner

as having long-standing difficulty adhering to antiretroviral therapy. Patients had been diagnosed
as HIV infected from 1985 through 1999, with a mean infection duration of 6.8 years. Adherence
to HIV management is difficult to measure, (20) but for this study, nonadherence was defined by
persistently high HIV viral load values (Roche Amplicor HIV RNA polymerase chain reaction
values of more than 10 000 copies/mL) despite prescribed antiretroviral treatment, frequently
occurring together with poor clinic attendance and self-reported poor adherence. These clients
were referred to the adherence counselor. Table 1 details the plan for implementation of
adherence counseling.

On referral, the adherence counselor, who was also a registered nurse and family therapist,
performed a comprehensive medical and psychosocial assessment of each client for his or her
ability to adhere to therapy. The assessment occurred in a location identified by the client as
comfortable for him or her. The adherence counselor provided intense, full-time, one-on-one
education, nursing support, and comprehensive adherence resources (eg, directly observed
therapy, phone calls, pharmacy pickups, pillboxes) tailored to the individual needs of the client
and as agreed to by the client. A client-centered plan was developed based on the individual
client's strengths and weaknesses, level of understanding, psychosocial situation, and motivation.
Necessary referrals were made to maximize support. Weekly progress and achieved adherence
goals were recorded in a client record. Pill counts as well as self-report were used to determine
adherence to regimens. Medical aspects of the client's care were not purposefully manipulated.
The IMB (18) methodology was used to structure care plans and encourage behavior change.
This model incorporates provision of information and intense education about the disease and
medication used for treatment and includes a motivational component to reinforce the
importance of adherence and to offer support and encouragement while providing follow-up
immediately after the client starts taking medication or changes medication. The client is then
helped to build behavioral self-care skills such as accurately filling a pillbox, reordering
medication from the pharmacy, and identifying cues during activities of living to serve as
reminders of scheduled doses. Vital to the care plan were interventions including assessment of
adherence barriers, reinforcement of importance of adherence, and support encouragement at
follow-up visits.
Quantitative measurements were performed 6 months before baseline (obtained retrospectively),
at baseline (first contact with the adherence counselor), and then prospectively at 6 and 12
months after the introduction of the adherence counselor. CD4 counts, HIV RNA (viral load)
values, and patient weights were recorded using codes for each client. Treatment regimens were
selected by the infectious disease clinicians providing care for all patients, using contemporary
AIDS treatment guidelines. (1)
A one-on-one confidential client interview was conducted after the study was completed at 12
months. Clients discussed their experiences and evaluated the benefit of the Adherence
Counselor Program. To prevent bias, a trained interviewer who was previously unknown to the
client and was never involved in the client's care conducted the interviews. The interviewer
followed a scripted format of questions to provide consistency. The questions focused on views

and feelings of living with HIV/AIDS before the intervention, working with the adherence
counselor, medication taking, the quality and success of the treatment plan, the value of the
program, the least helpful components of the program, and advice the client would offer other
HIV-positive clients and practitioners working with HIV-positive clients. All clients, completer
and noncompleters, who were reachable by phone were invited to participate in the confidential
interview. Interviews were held either in a room within the hospital complex or at the client's
home, according to the client's preference. Interviewee comments were deidentified by the
interviewer before transmission to the investigators. Each client who completed the interview
process was given $25.00 for his or her time. Interviews were audiotaped, transcribed verbatim,
and reviewed for common themes. Clients were given the opportunity to review the transcribed
data to ensure accuracy in transcription. Informed consent was obtained before enrollment
pursuant to institutional review board approval of the study.
Data Analysis
Forty-six nonadherent HIV-infected adults were entered in the adherence program study.
Twenty-eight patients (61%) completed 1-year follow-up in the program, 8 were lost to followup or refused follow-up, and 5 died during the course of the year. Four patients elected no
antiviral therapy, and 1 patient was eliminated because of a lack of a complete set of data before
the start of the study. Mean values of serial CD4, HIV RNA, and weight for all 28 completers
were compared over time; statistical conclusions were drawn by analysis of variance with a
priori contrasts. Individual clients were further evaluated with respect to changes in viral load
using the following definitions: patients were arbitrarily categorized as likely to be either
adherent (viral load less than 400 copies/ mL), moderately adherent (viral load of 400-10 000
copies/ mL), or nonadherent (viral load greater than 10 000 copies/mL). Changes in individual
CD4 counts over time were also categorized as likely to be either nonadherent (increase relative
to baseline less than 25%) or adherent (increase greater than 25%). Changes in these parameters
were evaluated by the Wilcoxon signed rank test.
Results
As Treated
After the introduction of the adherence counselor, mean CD4 counts increased significantly (P <
.05) from baseline counts (mean [+ or -] 1 SD; 244 [+ or -]240 cells/[mm.sup.3]) to 6 month (290
[+ or -]268 cells/[mm.sup.3]) and 12 month counts (306 [+ or -] 272 cells/[mm.sup.3])(Figure
1A). Viral load values decreased significantly only between baseline and 6-month assessments
(147 880 [+ or -] 200 423 vs 61 190 [+ or -] 137 296 copies/ mL)(Figure 1B). The percentage of
patients with at least moderate adherence based on viral load increased significantly (P < .05)
between baseline and 6 months (7% vs 57%) and between baseline and 12 months (7% vs 43%)
(Table 2). Patients with at least moderate adherence were more likely than nonadherent patients
to experience an increase of at least 25% in CD4 counts at 6 months (68% vs 25%). No
statistically significant change in patient weight was appreciated, despite a trend to increase
(Figure 1C). Viral load values, more than even CD4 counts, demonstrated wide variability
(range, <50-750 000 copies/mL), resulting in high standard deviation values (Figure 2).

Intent to Treat
Although mean CD4 counts rose (Figure 3), only 61% of the 46 patients who entered the
program completed a full year of follow-up, and only one quarter (26%) had become at least
moderately adherent by the end of 1 year. Based on more stringent criteria, only 4 (8.7%) of 46
patients had become fully adherent by all 3 measures: self-report, investigators' consensus, and
viral load values less than 400 copies/mL. Eight patients were lost to follow-up or had moved, 5
patients died, 4 patients elected to discontinue HAART, and 1 patient was eliminated because of
an incomplete data set before study entry.
Qualitative Data Analysis
Qualitative data from 10 patient interviews were transcribed and separated into 4 types of data:
perceptions before the intervention, perceptions at the beginning of the intervention, perceptions
during the program, and reflective advice from the patient. The authors and the interviewer
identified themes for each of these periods. In the first stage, feelings of denial and isolation were
a common theme. Denial is a way of protecting oneself from the shock of the disclosure of a
terminal illness. For some patients, denial is needed until death. For many patients, denial
provides the needed time to understand the diagnosis and organize more lasting coping
mechanisms. Most participants described the time period before this intervention, which ranged
from a few years to more than a decade, as a time of denial, fear, depression, and shock. Some
examples of comments to support this theme of denial were "I didn't want to be around nobody; I
was all by myself"; " I didn't understand it; I tried to hide myself"; and "I was ashamed and
embarrassed." Some clients recognized the denial and told the interviewer "Big denial"; "It
wasn't reality"; "It was something they were just saying"; "I wasn't facing that I had it"; and "It
was hectic, shocking; I was in denial for a long time with it." In our study group, we saw
evidence of clients' using illicit street drugs to avoid dealing with the HIV diagnosis. Excerpts
from interviews include the following: "I was still running the streets/drugging, because I wanted
to forget" and "I was into drugs, cocaine, and drinking."
Difficulty with medications was another theme during the interval before the intervention. All of
the subjects made statements regarding various aspects of medication taking that impeded the
ability to adhere to regimens, including references to side effects, number of pills, and pill
fatigue. In fact, one client stated, "I just hate taking medication." Other examples of statements
relating to this issue included side effects and the amount of pills: "Pills made me sick, I hurt, felt
better not taking them"; "Made me nauseous, it affected my attitude, felt funny and woozy";
"Never took my meds before [the adherence counselor], I couldn't--there were too many"; and "I
was taking like 16 drugs a day, and I was tired of it."

In the beginning of the intervention, once the patient agreed to work with the adherence
counselor, an individualized plan was prepared (see Methods above). At first, some of the
patients resisted the efforts of the counselor. Such patients are often perceived as difficult and
ungrateful and frequently provoke undesired reactions from those who try to care for them. One
subject commented on the value of persistence on behalf of the adherence counselor: "At first I

didn't want to work with nobody because I didn't feel like I needed to." Other comments included
the following: "When she was calling me, I kept flushing her off, but she kept calling, which was
cool"; "At first I didn't want to work with her, because I didn't want nobody to get into my
business, then I came around"; and even "She gave me the pillboxes, showed me how to lay
them out, but when I got home, I would throw them in the garbage."
The HIV education portion of the program was well received. Excerpts to verify this finding
include the following: "I started learning about it and taking it more seriously"; "The more I
learn, the better it helps me"; "I got a book to see what each pill means, a pamphlet to read up on
it, a card to write it down, so I didn't forget"; and "I realized, no more fooling around." A benefit
of working one-on-one with a caring counselor was the improvement in communication. Even
though the counselor asked a lot of questions, clients felt this questioning was helpful because
they started communicating with someone about their disease.

During the study, subjects revealed 3 things that challenged them in adhering to the medication
program. One issue was the medications: the antiretroviral pills, the amount, the need to eat or
not to eat with medications, the size of the pills, and the side effects. Another challenge was peer
pressure to do illicit drugs and drink alcohol. A third challenge was apathy and depression,
mentioned by almost every interviewee. One participant stated, "Sometimes I think I am going to
die, too much stuff in my head."
Every participant in this study made positive statements about the qualities of the Adherence
Counselor Program. The words strength and power were noted throughout this part of the
interview. Patients felt the program helped them improve their situation. Spirituality was also a
common thread; most clients expressed a belief that God would continue to help them cope with
life. Having someone professional and confidential to share information with gave the clients a
better outlook on the future. Many patients stressed the value of confidentiality. The adherence
counselor's ability to be a good listener and to inspire was important to the interviewees, helping
them improve their outlook on the future and of their own abilities.
Cost
Program expenses were primarily attributable to salary and fringe benefits for the adherence
counselor. These expenses totaled approximately $61 350. Travel, telephone, and pager expenses
were approximately $1500. Adherence tools were mostly provided free by separately funded
state or local programs and pharmaceutical companies. Out-of-pocket expense for these items
was about $400. Meetings, staff education, and supplies expenses were budgeted at $1200. There
were no significant additional space or secretarial expenses. The total annual program cost, $64
450, benefited more than the 28 clients who completed this study. It included more than 1000
client contacts (including 300 patient visits in the immunology clinic) and at least monthly
contact with all the study clients, for an average cost per client contact of $48. Additional testing
and medical care attributable to better adherence was not factored into these computations.
Discussion

Poor adherence to HAART is common. Patients may miss up to one third of all medication
doses, and up to one fifth of the patients never fill their initial prescriptions. (10) Studies have
shown that for optimal viral suppression, patients must take more than 95% of prescribed doses.
Lesser degrees of adherence are associated with higher rates of virologic failure, immunologic
deterioration, and progression of clinical disease.

Multiple patient-focused interventions to increase adherence have been reported elsewhere to be
of value and were incorporated into our program. (21-27) These interventions included providing
financial counseling and support, providing free medication, streamlining medication schedules
to once or twice daily, and coordinating medication taking into the patient's daily living
schedule. The need to establish trust, provide spiritual support, utilize peer groups, provide
access to nonphysician caregivers, link viral load and CD4 counts to therapy, monitor and
aggressively treat adverse events, and share results with patients are all acknowledged and were
utilized by this program. Strategies also involved intense education regarding the purpose of the
medications, anticipated outcomes, importance of a medication schedule, and reportable side
effects. Directly observed therapy, medication boxes, handouts with times and medications, and
cue cards were used for each individual patient, as appropriate. Positive feedback and sharing
laboratory results with graphic displays and flowcharts also motivated patients' continued
adherence. It is crucial that patients and clinicians work together to achieve successful adherence
to medication therapy. (19,28)
Attempting to incorporate multiple adherence interventions into the context of a busy practice or
clinic may not be possible. A poorly motivated client becomes lost in this scenario; therefore, we
prospectively designed our study to add a dedicated adherence counselor to the care of a
historically nonadherent group. Our concept was to provide customized, individual attention to
each of the 46 clients enrolled in this program. Such attention was not limited to clinic time but
was completely flexible to fit in with the client's availability and perceived individual needs. This
program benefited all the clients using the immunology clinic as well as the 28 clients
participating in the study, averaging $48 per client contact and $64 450 annually.

After intense adherence management for 1 year, we were able to recruit about one quarter of
these clients into improving their behavior into what we judged at least moderately adherent, and
8.6% actually achieved full virologic suppression. Perhaps also noteworthy, 60% actually
became compliant enough to allow serologic follow-up every 3 to 6 months. Because we did not
assess for preexisting drug resistance, it is possible that a larger percentage would have become
virologically suppressed if treatment had been customized according to viral genotype or
phenotype. In our qualitative evaluation, many clients clearly expressed that their improved
performance was attributable to the adherence counselor.
This study illustrates the value that a dedicated adherence counselor may have in promoting
clients' adherence to antiretroviral therapy and, in the very least, to maintain connection to their
health care. Only 8, or 17%, of the 46 clients we identified as recalcitrant were lost to follow-up;

61% completed the program. Although there may be features unique to our study site and to our
adherence counselor, there are some clients who will always refuse treatment options and
support. There is certainly value to dedicated adherence counseling time in HIV management,
which may help reduce the risk of loss to follow-up and improve patient monitoring. Success in
such programs will undoubtedly promote better clinical outcomes and should retard the
development of antiretroviral drug resistance.
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Table 1. Plan for Implementation of Adherence Counseling
1.
2.

3.

Medical provider refers client to adherence counselor.
On receipt of referral, schedule an appropriate time to do initial
assessment (medical and psychosocial). Assessment is
done at the client's home, the hospital, by phone contact, or
any appropriate site where the client is comfortable.
Assess clients' strengths and weaknesses to enhance adherence,

4.
5.

6.

7.

8.
9.

level of understanding of the disease and the need for medication,
physical, and psychosocial situation that may influence
adherence, skills to effectively master adherent practices, and
client motivation.
Develop a client-centered care plan.
Provide adherence tools (eg, phone calls, pillboxes, beepers,
picture charts, written instructions, rewards or incentives,
home visits).
Offer daily contact with client at onset (telephone, visits) to
include directly observed therapy, if appropriate, and taper as
tolerated according to adherence achieved.
Assist client with obtaining necessary support for maximizing
adherence to medication and/or treatment (eg, referral to
Ryan White case manager, pharmacist, drug counseling, medical
and social programs, community resources, pastor, family,
friends, peer support groups).
Track progress of meeting medication adherence goal in client
record at least weekly.
Meet weekly with care team, including HIV nurse practitioner,
physicians, Ryan White case manager.

Table 2. Ranges of Viral Load and CD-4 Count Values in
Patients Who Completed 1 Year of Follow-up With the
Adherence Counselor *
HIV RNA, copies/mL
Range

Baseline

6 mo

12 mo

0-10 000
10 000-100 000
>100 000

2 (7)
14 (50)
12 (43)

16 (57)
8 (29)
4 (14)

12 (43)
10 (36)
6 (21)

CD4 absolute counts, cells/[mm.sup.3]
Range

Baseline

6 mo

12 mo

<200
201-350
>350

14 (50)
6 (21)
8 (29)

11 (39)
10 (36)
7 (25)

12 (43)
9 (32)
7 (25)

* Values are presented as no.(%).
Figure 1 A, mean CD4 count values for the group of 28 patients
completing 12 months of treatment. B, mean HIV RNA values
(viral load, in copies/mL) for the group of 28 patients completing
12 months of treatment. C, mean patient weight, in
pounds, for the group of 28 patients completing 12 months
of treatment.
A
6 months prior
Immediately prior
6 months after
12 months after

Mean CD4 count
261
244
290
306

B
6 months prior
Immediately prior
6 months after
12 months after
C
6 months prior
Immediately prior
6 months after
12 months after

Mean Viral Load
61,011
97,175
61,189
92,789
Mean Weight
154.8
155.6
156.3
157.9

Note: Table made from bar graphs.

